In June, Novant and CHS called off the deal, forcing CHS to seek out another buyer while it pursued a divestment plan to yield more than $1 billion in sales.
NYU Langone Health recently launched a molecular oncology program with clinical, research, and educational elements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback